Compare versions

--- version:Introduced
+++ version:(document, no version)
@@ -1,76 +1,35 @@
-SECOND REGULAR SESSION
-HOUSE RESOLUTION NO. 4661
-103RD GENERAL ASSEMBL Y
-INTRODUCED BY REPRESENT A TIVE HRUZA.
-7534H.01I JOSEPH ENGLER, Chief Clerk
-WHEREAS, an estimated 35.5 million adults in the United States, or fifteen percent,
-2 have chronic kidney disease, and nine out of ten adults with kidney disease do not know they
-3 have it; and
-4
-5 WHEREAS, cardiovascular disease is the leading cause of death in the United States,
-6 accounting for one in every three deaths, or a death due to cardiovascular disease every thirty-
-7 four seconds; and
-8
-9 WHEREAS, cardiovascular -kidney-metabolic syndrome is defined as a health
-10 disorder due to connections among heart disease, kidney disease, diabetes, and obesity
-11 leading to poor health outcomes; and
-12
-13 WHEREAS, chronic kidney disease significantly increases the risk of heart attack,
-14 stroke, and heart failure, and cardiovascular disease is the leading cause of death for
-15 individuals with kidney disease; and
-16
-17 WHEREAS, Medicare spends about $130 billion on kidney disease, with forty-five
-18 percent of dialysis patients being dually eligible for Medicare and Medicaid; and
-19
-20 WHEREAS, cardiovascular disease cost about $417.9 billion in health care services,
-21 medicines, and loss of productivity due to death in 2020 and 2021 alone; and
-22
-23 WHEREAS, in 2023, Medicaid per -person per -year spending was four hundred
-24 twenty-five percent higher for adults under sixty-five years of age with chronic kidney
-25 disease and heart failure ($28,534) compared to those without chronic kidney disease or heart
-26 failure ($5,440), and dual-eligible spending was one hundred forty-six percent higher for
-27 adults sixty-five years of age or older with chronic kidney disease and heart failure ($56,045)
-28 compared to those without chronic kidney disease or heart failure ($22,803); and
-29
-30 WHEREAS, geographic barriers and limited access to specialty care can delay
-31 diagnosis of chronic kidney disease in rural and remote communities; and
-32
-33 WHEREAS, tar geted screening can support earlier identification and referral,
-34 particularly in primary care settings; and
-35
-36 WHEREAS, there are cost-effect ive, easily accessible blood and urine tests to
-37 diagnose chronic kidney disease; and
-38
-39 WHEREAS, failing to identify the presence of chronic kidney disease or
-4 0 cardiovascular disease can lead to adverse health ef fects for patients and increased costs to
-41 the health care system; and
-42
-43 WHEREAS, early identification of kidney disease through routine screening,
-44 particularly for individuals with hypertension, diabetes, cardiovascular disease, or a family
-45 history of kidney disease, can dramatically slow disease progression and reduce
-4 6 cardiovascular complications; and
-47
-48 WHEREAS, community-based education, culturally appropriate care, and
-4 9 coordinated management of kidney and heart health have been shown to improve
-50 outcomes, reduce hospitalizations, and lower long-term health care costs:
-51
-52 NOW THEREFORE BE IT RESOL VED that we, the members of the Missouri
-53 House of Representatives, One Hundred Third General Assembly , Second Regular Session,
-54 hereby encourage:
-55
-56 (1) Continued evaluation of tar geted screening approaches for at-risk populations,
-57 particularly in rural and underserved areas of the state, to identify individuals with chronic
-58 kidney disease;
-59
-60 (2) The Missouri Department of Health and Senior Services to consider public-private
-61 collaborations to educate patients and health care providers on the importance of urine
-62 albumin-to-creatinine ratio screening to help uncover signs of early , and possibly treatable,
-63 kidney damage that other routine screenings may miss; and
-64
-65 (3) The Centers for Medicare and Medicaid Services to update recommendations or
-66 guidelines to increase access to complete cardiovascular -kidney screening for at-risk
-HR 4661 2
-67 Medicare and Medicaid populations and ensure that screening and management translate into
-68 improved clinical care through robust quality measurement and incentives.
-✔
-HR 4661 3
+MISSOURI HOUSE OF REPRESENTATIVES
+WITNESS APPEARANCE FORM
+HR 4661
+BILL NUMBER: DATE:
+4/23/2026
+COMMITTEE:
+Health and Mental Health
+IN SUPPORT OF IN OPPOSITION TO FOR INFORMATIONAL PURPOSESTESTIFYING:
+WITNESS NAME
+BUSINESS/ORGANIZATION:
+WITNESS NAME:
+ARNIE C. AC "HONEST-ABE" DIENOFF
+PHONE NUMBER:
+314-440-9000
+BUSINESS/ORGANIZATION NAME:
+STATE PUBLIC ADVOCACY
+TITLE:
+STATE PUBLIC ADVOCATE
+ADDRESS:
+P.O. BOX #1535
+CITY:
+O' FALLON
+STATE:
+MO
+ZIP:
+63366
+ArnieDienoff@Mail.Com
+EMAIL:
+In-Person
+ATTENDANCE:
+4/23/2026 11:59 PM
+SUBMIT DATE:
+THE INFORMATION ON THIS FORM IS PUBLIC RECORD UNDER CHAPTER 610, RSMo.
+I am in Support of this House Resolution and getting Missourians Testing faster and more accessible
+to Rural Counties of Our Great State by the Department of Public Health and Senior Services.